-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com
InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com
Stock analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR – Get Rating) in a report issued on Sunday. The firm set a "sell" rating on the stock.
InspireMD Price Performance
NSPR opened at $1.71 on Friday. InspireMD has a fifty-two week low of $1.68 and a fifty-two week high of $4.68. The firm's fifty day moving average price is $1.85 and its two-hundred day moving average price is $2.25. The company has a market capitalization of $14.22 million, a P/E ratio of -0.77 and a beta of 1.20.
Get InspireMD alerts:InspireMD (NYSE:NSPR – Get Rating) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.59) earnings per share for the quarter. InspireMD had a negative return on equity of 54.85% and a negative net margin of 334.66%. The business had revenue of $1.53 million for the quarter.
About InspireMD
(Get Rating)InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.
Recommended Stories
- Get a free copy of the StockNews.com research report on InspireMD (NSPR)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.
Stock analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR – Get Rating) in a report issued on Sunday. The firm set a "sell" rating on the stock.
StockNews.com的股票分析师在周日发布的一份报告中对InSpireMD(纽约证券交易所代码:NSPR-GET Rating)的股票进行了报道。该公司对该股设定了“卖出”评级。
InspireMD Price Performance
InspirreMD性价比
NSPR opened at $1.71 on Friday. InspireMD has a fifty-two week low of $1.68 and a fifty-two week high of $4.68. The firm's fifty day moving average price is $1.85 and its two-hundred day moving average price is $2.25. The company has a market capitalization of $14.22 million, a P/E ratio of -0.77 and a beta of 1.20.
NSPR上周五开盘报1.71美元。InSpireMD的52周低点为1.68美元,52周高位为4.68美元。该公司的50日移动均线价格为1.85美元,200日移动均线价格为2.25美元。该公司市值为1,422万美元,市盈率为-0.77,贝塔系数为1.20。
InspireMD (NYSE:NSPR – Get Rating) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.59) earnings per share for the quarter. InspireMD had a negative return on equity of 54.85% and a negative net margin of 334.66%. The business had revenue of $1.53 million for the quarter.
InSpireMD(纽约证券交易所代码:NSPR-GET Rating)最近一次公布季度收益结果是在8月9日,星期二。该公司公布了本季度每股收益(0.59美元)。InSpireMD的净资产回报率为负54.85%,净利润率为负334.66%。该业务本季度的收入为153万美元。
About InspireMD
关于InspirreMD
InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.
InspirreMD公司是一家医疗设备公司,专注于开发专有的MicroNet支架平台技术并将其商业化,用于治疗欧洲、拉丁美洲、中东和亚太地区的血管和冠状动脉疾病。该公司提供用于颈动脉应用的CGuard颈动脉血栓预防系统,以及用于急性冠脉综合征患者的MGuard Prime血栓保护系统,特别是急性心肌梗死、大隐静脉移植冠状动脉介入治疗以及搭桥手术。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on InspireMD (NSPR)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- 免费获取StockNews.com关于InspirreMD的研究报告(NSPR)
- 第四季度值得考虑的3家银行
- 股市:红海中的三座强国
- 没有人告诉这三只股票这是下跌的一周
- 有什么办法可以治愈Teladoc股票的问题吗?
- MarketBeat:回顾一周9/12-9/16
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.
接受《InspirreMD日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对InSpireMD和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧